A. Tesoriero

发表

BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50

A. Whittemore, M. Pike, L. Andrews, 2006, Cancer Epidemiology Biomarkers & Prevention.

Is BRCA2 c.9079 G > A a predisposing variant for early onset breast cancer?

G. Giles, J. Hopper, M. Southey, 2008, Breast Cancer Research and Treatment.

ELAC 2 / HPC 2 Polymorphisms , Prostate-Specific Antigen Levels , and Prostate Cancer

D. English, P. Boyle, G. Giles, 2003 .

Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

G. Giles, J. Hopper, M. Southey, 1999, Cancer research.

Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

J. Hopper, A. Spurdle, M. Southey, 2006, Cancer research.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years.

G. Giles, J. Hopper, M. Southey, 2006, European journal of cancer.

Adaptive evolution of the tumour suppressor BRCA1 in humans and chimpanzees

Simon Easteal, Gavin A. Huttley, Graham G. Giles, 2000, Nature Genetics.

Two ATM variants and breast cancer risk

P. Oefner, J. Sambrook, G. Giles, 2005, Human mutation.

Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry

S. Fox, G. Giles, J. Hopper, 2011, Breast Cancer Research.

Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants

J. Hopper, A. Spurdle, J. Visvader, 2005, Journal of Medical Genetics.

Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.

John L Hopper, Graham G Giles, Melissa C Southey, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.

D. English, P. Boyle, G. Giles, 2003, Journal of the National Cancer Institute.

Is MSH2 a breast cancer susceptibility gene?

G. Giles, J. Hopper, M. Southey, 2007, Familial Cancer.

The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women

G. Giles, J. Hopper, A. Spurdle, 2008, Breast Cancer Research and Treatment.

The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels

D. English, P. Boyle, G. Giles, 2007, BJU international.

A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1

M. Southey, M. Jenkins, M. Young, 2003, Human mutation.

Morphological predictors of BRCA1 germline mutations in young women with breast cancer

M. Southey, J. Dowty, G. Dite, 2011, British Journal of Cancer.

A protein‐truncating mutation in CYP17A1 in three sisters with early‐onset breast cancer

G. Giles, J. Hopper, A. Spurdle, 2005, Human mutation.

De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation.

G. Giles, J. Hopper, M. Southey, 1999, American journal of human genetics.

The role of SMAD4 in early‐onset colorectal cancer

G. Giles, M. Southey, A. Haydon, 2010, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple‐case breast cancer families

A. Spurdle, G. Chenevix-Trench, M. Southey, 2005, Human mutation.